CL2007002670A1 - Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis. - Google Patents

Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis.

Info

Publication number: CL2007002670A1
Authority: CL; Chile
Prior art keywords: disorder; methylamineome; aterosclerosis; isoindoline; pain
Prior art date: 2006-09-15

Application number

CL200702670A

Other languages

English (en)

Inventor

W Muller Y Roger S C Ch George

Original Assignee

Celgene Corp Soc Organizada Ba

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-15

Filing date

2007-09-14

Publication date

2008-05-16

2007-09-14 Application filed by Celgene Corp Soc Organizada Ba filed Critical Celgene Corp Soc Organizada Ba

2008-05-16 Publication of CL2007002670A1 publication Critical patent/CL2007002670A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

CL200702670A 2006-09-15 2007-09-14 Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis. CL2007002670A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US84522706P	2006-09-15	2006-09-15

Publications (1)

Publication Number	Publication Date
CL2007002670A1 true CL2007002670A1 (es)	2008-05-16

Family

ID=38983295

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200702670A CL2007002670A1 (es)	2006-09-15	2007-09-14	Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis.

Country Status (30)

Country	Link
US (2)	US8648096B2 (es)
EP (1)	EP2076260B1 (es)
JP (1)	JP5567339B2 (es)
KR (1)	KR20090050107A (es)
CN (2)	CN101534820A (es)
AR (1)	AR062875A1 (es)
AT (1)	ATE502634T1 (es)
CA (1)	CA2663376C (es)
CL (1)	CL2007002670A1 (es)
CO (1)	CO6180446A2 (es)
CR (1)	CR10696A (es)
CY (1)	CY1112558T1 (es)
DE (1)	DE602007013436D1 (es)
DK (1)	DK2076260T3 (es)
ES (1)	ES2361584T3 (es)
HR (1)	HRP20110261T1 (es)
IL (1)	IL197566A0 (es)
MX (1)	MX2009002666A (es)
NI (1)	NI200900031A (es)
NZ (1)	NZ575689A (es)
PE (1)	PE20080832A1 (es)
PL (1)	PL2076260T3 (es)
PT (1)	PT2076260E (es)
RS (1)	RS51725B (es)
RU (1)	RU2009114159A (es)
SI (1)	SI2076260T1 (es)
TW (1)	TW200819435A (es)
UA (1)	UA95975C2 (es)
WO (1)	WO2008033567A1 (es)
ZA (1)	ZA200901852B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA200702382B (en) *	2004-09-03	2008-08-27	Celgene Corp	Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines
AU2006265019B2 (en) *	2005-06-30	2011-10-13	Celgene Corporation	Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
CN101534820A (zh) *	2006-09-15	2009-09-16	细胞基因公司	N-甲基氨甲基异吲哚化合物和包含它的组合物及其使用方法
US20100160368A1 (en)	2008-08-18	2010-06-24	Gregory Jefferson J	Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
MX2011004470A (es)	2008-10-29	2011-05-31	Celgene Corp	Compuestos de isoindolina para uso en el tratamiento de cancer.
US20110021555A1 (en)	2008-12-19	2011-01-27	Graceway Pharmaceuticals, Llc	Lower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratoses
US20110207766A1 (en)	2009-07-13	2011-08-25	Graceway Pharmaceuticals, Llc.	Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
MX337169B (es)	2010-02-11	2016-02-16	Celgene Corp	Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos.
WO2012135299A1 (en)	2011-03-28	2012-10-04	Deuteria Pharmaceuticals Inc	2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
CA2935495C (en)	2013-01-14	2021-04-20	Deuterx, Llc	3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
LT2970132T (lt)	2013-03-14	2021-01-11	Epizyme, Inc.	Argininmetiltransferazės inhibitoriai ir jų panaudojimas
US9120757B2 (en)	2013-03-14	2015-09-01	Epizyme, Inc.	Arginine methyltransferase inhibitors and uses thereof
JP2016514164A (ja)	2013-03-14	2016-05-19	エピザイム，インコーポレイティド	アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用
WO2014152833A1 (en)	2013-03-14	2014-09-25	Deuterx, Llc	3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014144659A1 (en)	2013-03-14	2014-09-18	Epizyme, Inc.	Pyrazole derivatives as prmt1 inhibitors and uses thereof
US20160039767A1 (en)	2013-03-14	2016-02-11	Epizyme, Inc.	Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014153208A1 (en)	2013-03-14	2014-09-25	Epizyme, Inc.	Arginine methyltransferase inhibitors and uses thereof
WO2014153100A2 (en)	2013-03-14	2014-09-25	Epizyme, Inc.	Arginine methyltransferase inhibitors and uses thereof
WO2014153214A1 (en)	2013-03-14	2014-09-25	Epizyme, Inc.	Arginine methyl transferase inhibtors and uses thereof
EP2970220A2 (en)	2013-03-14	2016-01-20	Epizyme, Inc.	Arginine methyltransferase inhibitors and uses thereof
WO2014153172A1 (en)	2013-03-14	2014-09-25	Epizyme, Inc.	Pyrazole derivatives as prmt1 inhibitors and uses thereof
JP6389241B2 (ja)	2013-04-17	2018-09-12	シグナルファーマシューティカルズ，エルエルシー	癌を治療するためのＴＯＲキナーゼ阻害剤及びＩＭｉＤ化合物を含む組合せ療法
UA117141C2 (uk)	2013-10-08	2018-06-25	Селджин Корпорейшн	Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
BR112017002403A2 (pt)	2014-08-07	2017-12-05	Calithera Biosciences Inc	formas de cristais de inibidores de glutaminase
DK3214081T3 (da) *	2014-10-30	2020-09-28	Kangpu Biopharmaceuticals Inc	Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf
US9809603B1 (en)	2015-08-18	2017-11-07	Deuterx, Llc	Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
US10449168B2 (en)	2015-08-31	2019-10-22	The University Of Toledo	Potent phthalate inhibitors of aspartate N-acetyltransferase and selective aspartate pathway inhibitors
EA034514B1 (ru)	2015-12-15	2020-02-14	Астразенека Аб	Изоиндольные соединения
US10759808B2 (en) *	2016-04-06	2020-09-01	The Regents Of The University Of Michigan	Monofunctional intermediates for ligand-dependent target protein degradation
WO2017197046A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197055A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	Heterocyclic degronimers for target protein degradation
CN109562113A (zh)	2016-05-10	2019-04-02	C4医药公司	用于靶蛋白降解的螺环降解决定子体
SG11201903483VA (en)	2016-10-28	2019-05-30	Icahn School Med Mount Sinai	Compositions and methods for treating ezh2-mediated cancer
WO2018106870A1 (en)	2016-12-08	2018-06-14	Icahn School Of Medicine At Mount Sinai	Compositions and methods for treating cdk4/6-mediated cancer
CN110730780A (zh)	2017-06-14	2020-01-24	阿斯利康(瑞典)有限公司	用作ROR-γ调节剂的2，3-二氢异吲哚-1-甲酰胺
WO2018237026A1 (en)	2017-06-20	2018-12-27	C4 Therapeutics, Inc.	N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
WO2019043208A1 (en)	2017-09-04	2019-03-07	F. Hoffmann-La Roche Ag	DIHYDROQUINOLINONES
EP3679027A1 (en)	2017-09-04	2020-07-15	C4 Therapeutics, Inc.	Dihydrobenzimidazolones
EP3679026A1 (en)	2017-09-04	2020-07-15	C4 Therapeutics, Inc.	Glutarimide
WO2019099868A2 (en)	2017-11-16	2019-05-23	C4 Therapeutics, Inc.	Degraders and degrons for targeted protein degradation
US11472799B2 (en)	2018-03-06	2022-10-18	Icahn School Of Medicine At Mount Sinai	Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
JP2021519337A (ja)	2018-03-26	2021-08-10	シー４セラピューティクス，インコーポレイテッド	Ｉｋａｒｏｓの分解のためのセレブロン結合剤
WO2019204354A1 (en)	2018-04-16	2019-10-24	C4 Therapeutics, Inc.	Spirocyclic compounds
ES2959622T3 (es) *	2018-04-23	2024-02-27	Celgene Corp	Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para tratar el linfoma
EP3578561A1 (en)	2018-06-04	2019-12-11	F. Hoffmann-La Roche AG	Spiro compounds
CA3130469A1 (en)	2019-04-12	2020-10-15	C4 Therapeutics, Inc.	Tricyclic degraders of ikaros and aiolos
MX2022004727A (es)	2019-10-21	2022-05-13	Celgene Corp	Metodos de tratamiento de la leucemia linfocitica cronica con 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il)metil)benzil)amino)isoindolina-1,3-diona.
AU2020372333A1 (en) *	2019-10-21	2022-04-28	Celgene Corporation	Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CN110746400B (zh) *	2019-11-07	2021-12-17	郑州大学	一种靶向雄激素受体的荧光探针及其制备方法
JP2024504932A (ja)	2021-01-13	2024-02-02	モンテローザセラピューティクス，インコーポレイテッド	イソインドリノン化合物
CN115504963A (zh) *	2021-06-22	2022-12-23	苏州开拓药业股份有限公司	一种c-Myc蛋白降解剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6281230B1 (en) *	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) *	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
BR9908811A (pt) *	1998-03-16	2000-12-05	Celgene Corp	Composto, composição farmacêutica e seu uso no tratamento de mamìferos
US7091353B2 (en) *	2000-12-27	2006-08-15	Celgene Corporation	Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) *	2000-12-27	2003-03-06	Robarge Michael J.	Isoindole-imide compounds, compositions, and uses thereof
US7968569B2 (en) *	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
CA2508171C (en) *	2002-12-13	2012-08-28	Cytopia Pty Ltd	Nicotinamide-based kinase inhibitors
US20050143344A1 (en) *	2003-12-30	2005-06-30	Zeldis Jerome B.	Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
AU2006265019B2 (en) *	2005-06-30	2011-10-13	Celgene Corporation	Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
CN101534820A (zh) *	2006-09-15	2009-09-16	细胞基因公司	N-甲基氨甲基异吲哚化合物和包含它的组合物及其使用方法

2007
- 2007-09-14 CN CNA2007800424312A patent/CN101534820A/zh active Pending
- 2007-09-14 MX MX2009002666A patent/MX2009002666A/es active IP Right Grant
- 2007-09-14 RU RU2009114159/15A patent/RU2009114159A/ru not_active Application Discontinuation
- 2007-09-14 US US11/901,291 patent/US8648096B2/en active Active
- 2007-09-14 KR KR1020097006986A patent/KR20090050107A/ko not_active Application Discontinuation
- 2007-09-14 SI SI200730569T patent/SI2076260T1/sl unknown
- 2007-09-14 ZA ZA200901852A patent/ZA200901852B/xx unknown
- 2007-09-14 WO PCT/US2007/020201 patent/WO2008033567A1/en active Application Filing
- 2007-09-14 RS RS20110258A patent/RS51725B/en unknown
- 2007-09-14 AT AT07838415T patent/ATE502634T1/de active
- 2007-09-14 ES ES07838415T patent/ES2361584T3/es active Active
- 2007-09-14 NZ NZ575689A patent/NZ575689A/en not_active IP Right Cessation
- 2007-09-14 TW TW096134612A patent/TW200819435A/zh unknown
- 2007-09-14 DE DE602007013436T patent/DE602007013436D1/de active Active
- 2007-09-14 PT PT07838415T patent/PT2076260E/pt unknown
- 2007-09-14 CN CN2013102182141A patent/CN103382197A/zh active Pending
- 2007-09-14 CL CL200702670A patent/CL2007002670A1/es unknown
- 2007-09-14 UA UAA200903664A patent/UA95975C2/ru unknown
- 2007-09-14 EP EP07838415A patent/EP2076260B1/en active Active
- 2007-09-14 CA CA2663376A patent/CA2663376C/en active Active
- 2007-09-14 DK DK07838415.3T patent/DK2076260T3/da active
- 2007-09-14 JP JP2009528337A patent/JP5567339B2/ja active Active
- 2007-09-14 PL PL07838415T patent/PL2076260T3/pl unknown
- 2007-09-17 PE PE2007001253A patent/PE20080832A1/es not_active Application Discontinuation
- 2007-09-17 AR ARP070104112A patent/AR062875A1/es unknown
2009
- 2009-03-12 IL IL197566A patent/IL197566A0/en unknown
- 2009-03-13 NI NI200900031A patent/NI200900031A/es unknown
- 2009-03-30 CR CR10696A patent/CR10696A/es not_active Application Discontinuation
- 2009-04-03 CO CO09034806A patent/CO6180446A2/es not_active Application Discontinuation
2011
- 2011-04-12 HR HR20110261T patent/HRP20110261T1/hr unknown
- 2011-05-20 CY CY20111100500T patent/CY1112558T1/el unknown
2013
- 2013-12-30 US US14/144,292 patent/US20140113935A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL197566A0 (en)	2009-12-24
RS51725B (en)	2011-10-31
CA2663376A1 (en)	2008-03-20
JP5567339B2 (ja)	2014-08-06
JP2010503688A (ja)	2010-02-04
RU2009114159A (ru)	2010-10-20
HRP20110261T1 (hr)	2011-05-31
CO6180446A2 (es)	2010-07-19
US8648096B2 (en)	2014-02-11
ES2361584T3 (es)	2011-06-20
CN103382197A (zh)	2013-11-06
NZ575689A (en)	2011-12-22
PL2076260T3 (pl)	2011-08-31
CA2663376C (en)	2015-01-06
NI200900031A (es)	2010-02-01
WO2008033567A1 (en)	2008-03-20
PE20080832A1 (es)	2008-08-06
CY1112558T1 (el)	2016-02-10
DE602007013436D1 (de)	2011-05-05
DK2076260T3 (da)	2011-06-27
MX2009002666A (es)	2009-04-09
US20140113935A1 (en)	2014-04-24
SI2076260T1 (sl)	2011-05-31
TW200819435A (en)	2008-05-01
UA95975C2 (ru)	2011-09-26
CR10696A (es)	2009-05-13
KR20090050107A (ko)	2009-05-19
ZA200901852B (en)	2010-06-30
PT2076260E (pt)	2011-06-07
AR062875A1 (es)	2008-12-10
EP2076260B1 (en)	2011-03-23
EP2076260A1 (en)	2009-07-08
CN101534820A (zh)	2009-09-16
US20080214615A1 (en)	2008-09-04
ATE502634T1 (de)	2011-04-15

Publication	Publication Date	Title
CL2007002670A1 (es)	2008-05-16	Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis.
CL2013003393A1 (es)	2014-06-13	Inmunoconjugados (conjugados anticuerpo-fármaco) que en su estructura contienen un agente de unión al surco menor del adn (compuesto derivado de cbi), un grupo fosfato como grupo profármaco (protector) y un conector peptídico, útiles para el tratamiento de cáncer.
CL2013002593A1 (es)	2014-01-31	Forma cristalina a1 de la sal clorhidrato del compuesto 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una enfermedad o trastorno tal como cancer, angiogenesis, dolor, trastorno pulmonar y un trastorno del snc.
CL2007002650A1 (es)	2008-02-08	Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
IL255752B (en)	2021-10-31	Compounds, pharmaceutical preparations containing the same uses for the treatment of cardiovascular disease, inflammatory diseases and cancer
CL2008000348A1 (es)	2008-08-18	Compuestos derivados de carboxamida, inhibidores de la actividad de la proteina quinasa b; composicion farmaceutica; proceso para prepararla; y uso en el tratamiento de enfermedades tales como cancer y artritis.
CL2014000395A1 (es)	2014-12-05	Compuestos derivados de piridazinona sustituida; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de la esquizofrenia, trastorno esquizoafectivo, trastornos cognitivos o dolor.
CL2007003774A1 (es)	2008-04-18	Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
IL251175A0 (en)	2017-04-30	Stabilized dosage of picoplatin
CL2007002752A1 (es)	2008-07-11	Compuestos derivados de 3-(4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir enfermedades tales como cancer, dolor, degeneracion macular, trastorno pulmonar, tr
CL2007003341A1 (es)	2008-04-18	Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
WO2011060049A3 (en)	2011-10-20	Spiro-oxindole mdm2 antagonists
IL233677A (en)	2016-11-30	Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
CL2008001921A1 (es)	2008-10-17	Compuestos derivados de heterociclos sustituidos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ictus, isquemia cerebral, alzheimer, dolor, entre otras.
CL2008000690A1 (es)	2008-09-12	Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
WO2013188847A8 (en)	2015-02-05	Compositions and methods for transmucosal absorption
EA201070421A1 (ru)	2010-10-29	Микрорибонуклеиновые кислоты
BR112015003376A2 (pt)	2017-07-04	composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente
WO2012065022A3 (en)	2012-10-04	Spiro-oxindole mdm2 antagonists
CL2008001025A1 (es)	2008-10-17	Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer.
BRPI1009324A2 (pt)	2015-11-24	compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
WO2012062925A3 (en)	2012-07-12	Compounds and methods for treating pain
CL2007003049A1 (es)	2008-05-16	Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
CL2007003879A1 (es)	2008-07-04	Compuestos derivados de aril-carboxamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alzheimer, epilepsia y parkinson.
WO2009002808A3 (en)	2009-07-23	Quinazolinone compounds and methods of use thereof